- Home
- ILAG vs BCDA Comparison
ILAG vs BCDA Comparison
Compare ILAG & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILAG
- BCDA
- Stock Information
- Founded
- ILAG 1981
- BCDA N/A
- Country
- ILAG Hong Kong
- BCDA United States
- Employees
- ILAG N/A
- BCDA N/A
- Industry
- ILAG Office Equipment/Supplies/Services
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- ILAG Consumer Discretionary
- BCDA Health Care
- Exchange
- ILAG Nasdaq
- BCDA Nasdaq
- Market Cap
- ILAG 11.1M
- BCDA 11.3M
- IPO Year
- ILAG 2022
- BCDA N/A
- Fundamental
- Price
- ILAG $0.64
- BCDA $1.54
- Analyst Decision
- ILAG
- BCDA Strong Buy
- Analyst Count
- ILAG 0
- BCDA 1
- Target Price
- ILAG N/A
- BCDA $25.00
- AVG Volume (30 Days)
- ILAG 710.4K
- BCDA 94.6K
- Earning Date
- ILAG 04-28-2025
- BCDA 11-12-2025
- Dividend Yield
- ILAG N/A
- BCDA N/A
- EPS Growth
- ILAG N/A
- BCDA N/A
- EPS
- ILAG N/A
- BCDA N/A
- Revenue
- ILAG $7,506,551.00
- BCDA N/A
- Revenue This Year
- ILAG N/A
- BCDA N/A
- Revenue Next Year
- ILAG N/A
- BCDA N/A
- P/E Ratio
- ILAG N/A
- BCDA N/A
- Revenue Growth
- ILAG 16.50
- BCDA N/A
- 52 Week Low
- ILAG $0.34
- BCDA $1.54
- 52 Week High
- ILAG $1.15
- BCDA $3.25
- Technical
- Relative Strength Index (RSI)
- ILAG 54.88
- BCDA 29.50
- Support Level
- ILAG $0.60
- BCDA $2.11
- Resistance Level
- ILAG $0.67
- BCDA $2.29
- Average True Range (ATR)
- ILAG 0.08
- BCDA 0.12
- MACD
- ILAG 0.01
- BCDA -0.04
- Stochastic Oscillator
- ILAG 34.09
- BCDA 0.66
About ILAG Intelligent Living Application Group Inc.
Intelligent Living Application Group Inc focuses on designing and producing affordable, high-quality locksets and smart security systems. The company offers high-quality mechanical locksets and smart locks to its customers. Its product portfolio comprises various ODM indoor and outdoor locksets, such as deadbolts, entry locksets, privacy locksets, passage locksets, and storeroom locks, which are marketed through brands like Kambo and Bamberg. Geographically, the company generates a majority of its revenue from its customers in the United States and the rest from Canada.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).